Literature DB >> 27588731

Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry.

Jérémie Abtan1,2, Deepak L Bhatt3, Yedid Elbez1,2, Emmanuel Sorbets1,2, Kim Eagle4, Yasuo Ikeda5, David Wu6, Mary E Hanson6, Hakima Hannachi6, Puneet K Singhal6, Philippe Gabriel Steg1,2,7, Gregory Ducrocq1,2.   

Abstract

BACKGROUND: Although the rate of in-hospital ischemic events after myocardial infarction (MI) has dramatically decreased, long-term residual risk may remain substantial. However, most of the information on current residual risk is derived from highly selected randomized trials. HYPOTHESIS: In patients with previous MI and no prior ischemic stroke/transient ischemic attack (TIA), residual ischemic risk increases over time.
METHODS: Using the international Reduction of Atherothrombosis for Continued Health (REACH) registry, we analyzed baseline characteristics and 4-year follow-up of patients with previous MI and no history of stroke/TIA to describe annual rates of recurrent ischemic events globally and by geography. The primary outcome was the composite of cardiovascular death, MI, or stroke. Multivariate analysis identified risk factors associated with recurrent ischemic events.
RESULTS: Data from 16 770 patients enrolled at 5587 sites in 44 countries were analyzed. The rate of the primary outcome increased annually from 4.7% during year 1 to reach a 4-year rate of 15.1%. Compared with North America, Japan experienced lower ischemic event rates (P < 0.01), whereas Eastern Europe (P < 0.01) and the Middle East (P = 0.01) experienced higher ischemic event rates. The presence of congestive heart failure, polyvascular disease, diabetes, atrial fibrillation or flutter, and older age were associated with increased residual risk (all P < 0.01). Statin use was associated with lower ischemic risk (P < 0.01).
CONCLUSIONS: In this study, residual ischemic risk after MI accrued progressively up to 4 years of follow-up, emphasizing the value of intensive secondary prevention strategies to minimize residual risk.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ischemic heart disease; ischemic risk; myocardial infarction; vorapaxar

Mesh:

Year:  2016        PMID: 27588731      PMCID: PMC6490735          DOI: 10.1002/clc.22583

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  41 in total

1.  AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association.

Authors:  Sidney C Smith; Emelia J Benjamin; Robert O Bonow; Lynne T Braun; Mark A Creager; Barry A Franklin; Raymond J Gibbons; Scott M Grundy; Loren F Hiratzka; Daniel W Jones; Donald M Lloyd-Jones; Margo Minissian; Lori Mosca; Eric D Peterson; Ralph L Sacco; John Spertus; James H Stein; Kathryn A Taubert
Journal:  J Am Coll Cardiol       Date:  2011-11-03       Impact factor: 24.094

2.  An international model to predict recurrent cardiovascular disease.

Authors:  Peter W F Wilson; Ralph D'Agostino; Deepak L Bhatt; Kim Eagle; Michael J Pencina; Sidney C Smith; Mark J Alberts; Jean Dallongeville; Shinya Goto; Alan T Hirsch; Chiau-Suong Liau; E Magnus Ohman; Joachim Röther; Christopher Reid; Jean-Louis Mas; Ph Gabriel Steg
Journal:  Am J Med       Date:  2012-07       Impact factor: 4.965

3.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

4.  A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease.

Authors:  Gregory Ducrocq; Pierre Amarenco; Julien Labreuche; Mark J Alberts; Jean-Louis Mas; E Magnus Ohman; Shinya Goto; Philippa Lavallée; Deepak L Bhatt; Ph Gabriel Steg
Journal:  Circulation       Date:  2012-12-31       Impact factor: 29.690

Review 5.  PCSK9 inhibition in patients with hypercholesterolemia.

Authors:  Nihar R Desai; Marc S Sabatine
Journal:  Trends Cardiovasc Med       Date:  2015-02-11       Impact factor: 6.677

6.  Prasugrel versus clopidogrel in patients with acute coronary syndromes.

Authors:  Stephen D Wiviott; Eugene Braunwald; Carolyn H McCabe; Gilles Montalescot; Witold Ruzyllo; Shmuel Gottlieb; Franz-Joseph Neumann; Diego Ardissino; Stefano De Servi; Sabina A Murphy; Jeffrey Riesmeyer; Govinda Weerakkody; C Michael Gibson; Elliott M Antman
Journal:  N Engl J Med       Date:  2007-11-04       Impact factor: 91.245

7.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction.

Authors:  Etienne Puymirat; Tabassome Simon; Philippe Gabriel Steg; François Schiele; Pascal Guéret; Didier Blanchard; Khalife Khalife; Patrick Goldstein; Simon Cattan; Laurent Vaur; Jean-Pierre Cambou; Jean Ferrières; Nicolas Danchin
Journal:  JAMA       Date:  2012-09-12       Impact factor: 56.272

9.  Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes.

Authors:  Deepak L Bhatt; Eric D Peterson; Robert A Harrington; Fang-Shu Ou; Christopher P Cannon; C Michael Gibson; Neal S Kleiman; Ralph G Brindis; W Frank Peacock; Sorin J Brener; Venu Menon; Sidney C Smith; Charles V Pollack; W Brian Gibler; E Magnus Ohman; Matthew T Roe
Journal:  Eur Heart J       Date:  2009-04-01       Impact factor: 29.983

10.  Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events.

Authors:  Keith A A Fox; Kathryn Carruthers; Ph Gabriel Steg; Alvaro Avezum; Christopher B Granger; Gilles Montalescot; Shaun G Goodman; Joel M Gore; Ann L Quill; Kim A Eagle
Journal:  Eur Heart J       Date:  2009-12-08       Impact factor: 29.983

View more
  7 in total

1.  Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry.

Authors:  Jérémie Abtan; Deepak L Bhatt; Yedid Elbez; Emmanuel Sorbets; Kim Eagle; Yasuo Ikeda; David Wu; Mary E Hanson; Hakima Hannachi; Puneet K Singhal; Philippe Gabriel Steg; Gregory Ducrocq
Journal:  Clin Cardiol       Date:  2016-09-02       Impact factor: 2.882

2.  The Usefulness of Assessing Heart Rate Variability in Patients with Acute Myocardial Infarction (HeaRt-V-AMI).

Authors:  Crischentian Brinza; Mariana Floria; Adrian Covic; Andreea Covic; Dragos-Viorel Scripcariu; Alexandru Burlacu
Journal:  Sensors (Basel)       Date:  2022-05-07       Impact factor: 3.847

3.  Determinants of suboptimal long-term secondary prevention of acute myocardial infarction: the structural interview method and physical examinations.

Authors:  Maria Sakalaki; Salim Barywani; Annika Rosengren; Lena Björck; Michael Fu
Journal:  BMC Cardiovasc Disord       Date:  2019-11-06       Impact factor: 2.298

4.  Predictors of recurrent acute myocardial infarction despite successful percutaneous coronary intervention.

Authors:  Sang Hun Lee; Myung Ho Jeong; Joon Ho Ahn; Dae Young Hyun; Kyung Hoon Cho; Min Chul Kim; Doo Sun Sim; Young Joon Hong; Ju Han Kim; Youngkeun Ahn; Jin Yong Hwang; Weon Kim; Jong Seon Park; Chang-Hwan Yoon; Seung Ho Hur; Sang Rok Lee; Kwang Soo Cha
Journal:  Korean J Intern Med       Date:  2022-06-28       Impact factor: 3.165

Review 5.  2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome.

Authors:  Jack Wei Chieh Tan; Derek P Chew; David Brieger; John Eikelboom; Gilles Montalescot; Junya Ako; Byeong-Keuk Kim; David Kl Quek; Sarah J Aitken; Clara K Chow; Sok Chour; Hung Fat Tse; Upendra Kaul; Isman Firdaus; Takashi Kubo; Boon Wah Liew; Tze Tec Chong; Kenny Yk Sin; Hung-I Yeh; Wacin Buddhari; Narathip Chunhamaneewat; Faisal Hasan; Keith Aa Fox; Quang Ngoc Nguyen; Sidney Th Lo
Journal:  Eur Cardiol       Date:  2021-06-18

6.  Development and validation of a 2-year new-onset stroke risk prediction model for people over age 45 in China.

Authors:  Qiang Yao; Jing Zhang; Ke Yan; Qianwen Zheng; Yawen Li; Lu Zhang; Chenyao Wu; Yanling Yang; Muke Zhou; Cairong Zhu
Journal:  Medicine (Baltimore)       Date:  2020-10-09       Impact factor: 1.817

7.  Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia.

Authors:  Ahmed Alghamdi; Bander Balkhi; Abdulaziz Altowaijri; Nasser Al-Shehri; Lewis Ralph; Emily-Ruth Marriott; Michael Urbich; Fawaz Aljanad; Rima Aziziyeh
Journal:  Pharmacoecon Open       Date:  2021-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.